BBP - ETF AI Analysis

Top Page

Virtus LifeSci Biotech Products ETF (BBP)

Rating:62Neutral

Price Target:―

The Virtus LifeSci Biotech Products ETF (BBP) has a balanced rating, reflecting both strengths and challenges within its portfolio. Aurinia Pharmaceuticals stands out as a key contributor, driven by strong financial recovery, robust sales growth, and promising clinical developments, although its high valuation may introduce some volatility. On the other hand, holdings like Insmed and BridgeBio Pharma weigh on the ETF's rating due to financial instability and valuation concerns. A notable risk for this ETF is its concentration in the biotech sector, which can be highly volatile and sensitive to regulatory and market developments.

Positive Factors

Strong Year-to-Date Performance

The ETF has delivered solid year-to-date returns, indicating strong recent performance.

Focus on High-Growth Sector

The fund is heavily concentrated in the health care sector, which often benefits from innovation and long-term growth trends.

Top Holdings Showing Positive Momentum

Several of the top holdings, such as Ionis Pharmaceuticals and Insmed, have shown strong year-to-date gains, supporting the ETF's overall performance.

Negative Factors

High Sector Concentration

Nearly all of the ETF's exposure is in the health care sector, making it vulnerable to sector-specific risks.

Limited Geographic Diversification

The ETF is almost entirely focused on U.S.-based companies, offering little protection against international market opportunities or risks.

Above-Average Expense Ratio

The ETF charges a relatively high expense ratio compared to many other funds, which can eat into investor returns over time.

BBP vs. SPDR S&P 500 ETF (SPY)

AUM31.02M

RegionNorth America

Expense Ratio0.79%

Beta0.93

IssuerVirtus

Inception DateDec 17, 2014

Dividend YieldN/A

Asset ClassEquity

Index TrackedLifeSci Biotechnology Products Index

Share Statistics

EPS (TTM)N/A

Shares OutstandingN/A

10 Day Avg. Volume4,414

30 Day Avg. Volume4,319

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

109.48

Price Target Upside― Downside

Rating ConsensusStrong Buy

Number of Analyst Covering54

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

BBP Summary

The Virtus LifeSci Biotech Products ETF (BBP) focuses on the biotechnology sector within health care, offering exposure to companies developing cutting-edge medical treatments and technologies. It follows the LifeSci Biotechnology Products Index and includes innovative firms like Ionis Pharmaceuticals and Crispr Therapeutics. This ETF could be appealing to investors looking for growth opportunities in the rapidly evolving biotech industry or those seeking to diversify their portfolio with health care-focused investments. However, new investors should be aware that the ETF’s performance is heavily tied to the biotech sector, which can be volatile and influenced by regulatory changes or scientific breakthroughs.

How much will it cost me?The Virtus LifeSci Biotech Products ETF (BBP) has an expense ratio of 0.79%, which means you’ll pay $7.90 per year for every $1,000 invested. This is higher than average because it is actively managed, focusing on a specialized sector like biotechnology that requires more research and expertise.

What would affect this ETF?The Virtus LifeSci Biotech Products ETF (BBP) could benefit from advancements in biotechnology and increased demand for innovative medical treatments, particularly in the U.S., where it is focused. However, it may face challenges from regulatory hurdles, high research and development costs, or broader economic downturns that could impact funding and growth in the biotech sector.

BBP Top 10 Holdings

The Virtus LifeSci Biotech Products ETF is firmly rooted in the biotech sector, showcasing a mix of rising stars and steady performers. Insmed and BridgeBio Pharma are driving momentum with strong technical trends and promising growth prospects, though their financial challenges remain a concern. Meanwhile, Ionis Pharmaceuticals and Roivant Sciences are showing mixed results, with strategic advancements tempered by valuation and operational hurdles. The fund’s concentrated focus on U.S.-based biotech innovators offers exposure to cutting-edge medical breakthroughs, but the high-risk nature of the sector means investors should brace for volatility.

Name	Company Name	Weight %	Market Value	Market Cap	Yearly Gain	Overall Rating
TVTX	Travere Therapeutics	3.32%	$1.04M	$3.13B	101.10%	56 Neutral
IONS	Ionis Pharmaceuticals	3.14%	$987.35K	$12.82B	120.76%	61 Neutral
INSM	Insmed	2.85%	$895.57K	$41.64B	175.04%	54 Neutral
TARS	Tarsus Pharmaceuticals	2.82%	$886.61K	$3.47B	59.94%	60 Neutral
AUPH	Aurinia Pharmaceuticals	2.73%	$857.47K	$2.09B	69.16%	79 Outperform
MDGL	Madrigal Pharmaceuticals	2.72%	$854.14K	$12.98B	87.66%	56 Neutral
BBIO	BridgeBio Pharma	2.64%	$830.12K	$14.27B	173.37%	59 Neutral
RYTM	Rhythm Pharmaceuticals	2.64%	$829.46K	$7.85B	105.58%	59 Neutral
ROIV	Roivant Sciences	2.63%	$826.80K	$14.84B	86.66%	58 Neutral
KRYS	Krystal Biotech	2.49%	$781.54K	$7.16B	49.50%	80 Outperform

BBP Technical Analysis

Technical Analysis Sentiment

Positive

Last Price―

Price Trends

50DMA

75.14

Positive

100DMA

71.11

Positive

200DMA

64.63

Positive

Market Momentum

MACD

0.92

Positive

RSI

57.44

Neutral

STOCH

45.26

Neutral

Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For BBP, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 77.96, equal to the 50-day MA of 75.14, and equal to the 200-day MA of 64.63, indicating a bullish trend. The MACD of 0.92 indicates Positive momentum. The RSI at 57.44 is Neutral, neither overbought nor oversold. The STOCH value of 45.26 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BBP.

BBP Peer Comparison

Comparison Results

Name	Price	Price Target	AUM	Expense Ratio	Overall Rating
BBP	―	―	$31.02M	0.79%	―
LFSC	―	―	$98.61M	0.54%	―
XHS	―	―	$86.47M	0.35%	―
IBBQ	―	―	$58.31M	0.19%	―
BBC	―	―	$29.43M	0.79%	―
FTXH	―	―	$19.10M	0.60%	―

Performance Comparison

BBP

Virtus LifeSci Biotech Products ETF

78.81

16.49

26.46%

LFSC

F/M Emerald Life Sciences Innovation ETF

―

XHS

SPDR S&P Health Care Services ETF

―

IBBQ

Invesco Nasdaq Biotechnology ETF

―

BBC

Virtus LifeSci Biotech Clinical Trials ETF

―

FTXH

First Trust Nasdaq Pharmaceuticals ETF

―

Glossary

BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―

Table of Contents